Highly potent and selective CB2 receptor inverse agonist (Ki = 1.8 nM, EC50 = 2 nM). Displays 100-fold selectivity for CB2 receptors over CB1. Increases forskolin stimulated cAMP accumulation in CHO cells expressing human CB2 receptors. Inhibits leukocyte migration in a murine model of delayed-type hypersensitivity and inhibits antigen-induced lung eosinophilia in a mouse allergy model.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 539.64. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.85 mL||9.27 mL||18.53 mL|
|5 mM||0.37 mL||1.85 mL||3.71 mL|
|10 mM||0.19 mL||0.93 mL||1.85 mL|
|50 mM||0.04 mL||0.19 mL||0.37 mL|
References are publications that support the biological activity of the product.
Lunn et al (2006) A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J.Pharmacol.Exp.Ther. 316 780 PMID: 16258021
If you know of a relevant reference for SCH 336, please let us know.
View Related Products by Product Action
Keywords: SCH 336, SCH 336 supplier, SCH336, potent, selective, cannabinoid, 2, receptor, CB2, inverse, agonists, Receptors, 5815, Tocris Bioscience
Citations for SCH 336
Citations are publications that use Tocris products.
Currently there are no citations for SCH 336. Do you know of a great paper that uses SCH 336 from Tocris? Please let us know.
Reviews for SCH 336
There are currently no reviews for this product. Be the first to review SCH 336 and earn rewards!
Have you used SCH 336?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.